Clearside Biomedical to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Wednesday, November 10, 2021

Rhea-AI Summary

Clearside Biomedical (NASDAQ:CLSD) announced the date for its third quarter 2021 financial results, set for November 10, 2021, post-market close. A webcast and conference call will follow at 4:30 p.m. ET, allowing investors and stakeholders to discuss the results and receive corporate updates. The company focuses on innovative treatment delivery to the back of the eye through its proprietary suprachoroidal space (SCS) Microinjector platform. Clearside’s first product, XIPERE™, gained FDA approval in October 2021.

Positive

• XIPERE™ received FDA approval in October 2021, enhancing Clearside's product portfolio.

Negative

• None.

ALPHARETTA, Ga., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that its third quarter 2021 financial results will be reported on Wednesday, November 10, 2021 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domestic) or (213) 358-0959 (international) and entering conference code: 1698586. An archive of the webcast will be available for three months.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE^™ (triamcinolone acetonide injectable suspension) for suprachoroidal use, was approved by the U.S. Food and Drug Administration in October 2021. For more information, please visit www.clearsidebio.com.

Source: Clearside Biomedical, Inc.

FAQ

When will Clearside Biomedical report its third quarter 2021 financial results?

Clearside Biomedical will report its third quarter 2021 financial results on November 10, 2021, after the close of the financial markets.

What is the significance of FDA approval for XIPERE™?

FDA approval of XIPERE™ allows Clearside to offer a new treatment option for patients with sight-threatening eye diseases, leveraging their innovative SCS delivery system.

How can I access the webcast for Clearside Biomedical's financial results?

You can access the live and archived webcast on the Clearside Biomedical website under the Investors section.

What time is the conference call for Clearside Biomedical's Q3 2021 results?

The conference call for Clearside Biomedical's Q3 2021 results will take place at 4:30 p.m. Eastern Time on November 10, 2021.